iTeos Therapeutics, Inc. (ITOS) is a publicly traded company in the Unknown sector. Across all available filings, 32 corporate insiders have executed 433 transactions totaling $298.9M, demonstrating a bearish sentiment with -$108.5M in net insider flow. The most recent transaction on Aug 29, 2025 involved a transaction of 46,300 shares valued at $0.
No significant insider buying has been recorded for ITOS in the recent period.
No significant insider selling has been recorded for ITOS in the recent period.
Based on recent SEC filings, insider sentiment for ITOS is bearish with an Insider Alignment Score of 32/100 and a net flow of -$108.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at iTeos Therapeutics, Inc. (ITOS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 32 insiders are actively trading ITOS stock, having executed 433 transactions in the past 90 days. The most active insider is Aaron I. Davis (Executive), who has made 23 transactions totaling $78.6M.
Get notified when executives and directors at ITOS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 29, 2025 | Mcgrath Yvonne | Executive | Tender | 46,300 | $N/A | $0 | |
| Aug 29, 2025 | Gall Matthew | Executive | Tender | 89,429 | $N/A | $0 | |
| Aug 29, 2025 | Feltquate David | Executive | Tender | 47,000 | $N/A | $0 | |
| Aug 29, 2025 | Detheux Michel | Executive | Tender | 153,903 | $N/A | $0 | |
| Aug 29, 2025 | Detheux Michel | Executive | Tender | 94,027 | $N/A | $0 | |
| Aug 29, 2025 | Call Matthew | Executive | Tender | 161,898 | $N/A | $0 | |
| May 12, 2024 | Kolchinsky Peter | Executive | Other | 900,000 | $N/A | $0 | |
| May 10, 2024 | I. Davis Aaron | Executive | Award | 1,142,857 | $17.50 | $20.0M | Large |
| Dec 5, 2023 | Detheux Michel | Executive | Award | 30,000 | $N/A | $0 | |
| Dec 5, 2023 | Gall Matthew | Executive | Award | 41,000 | $N/A | $0 | |
| Dec 5, 2023 | Call Matthew | Executive | Award | 44,000 | $N/A | $0 | |
| Dec 5, 2023 | Mcgrath Yvonne | Executive | Award | 31,000 | $N/A | $0 | |
| Oct 12, 2023 | Gall Matthew | Executive | Purchase | 5,000 | $8.37 | $41.9K | |
| Aug 23, 2023 | I. Davis Aaron | Executive | Sale | 219,638 | $16.87 | $3.7M | Large |
| Aug 23, 2023 | I. Davis Aaron | Executive | Sale | 95,516 | $15.63 | $1.5M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 307 | $203.7M | 60.8% |
Purchase(P) | 30 | $95.2M | 28.4% |
Award(A) | 6 | $20.0M | 6.0% |
Other(J) | 12 | $14.4M | 4.3% |
Exercise(M) | 29 | $1.5M | 0.5% |
Tender(U) | 6 | $0 | 0.0% |
Conversion(C) | 43 | $0 | 0.0% |
Insider selling pressure at iTeos Therapeutics, Inc. has increased, with 32 insiders executing 433 transactions across all time. Total sales of $203.7M significantly outpace purchases of $95.2M, resulting in a net outflow of $108.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.